Enhanced Type I Interferon Signalling Promotes Th1-biased Inflammation in Cutaneous Lupus Erythematosus
Authors
Affiliations
Recent studies have suggested that type I interferons (IFN) play a role in the pathogenesis of lupus erythematosus (LE), an autoimmune disease of unknown aetiology. Natural interferon-producing plasmacytoid cells have been demonstrated in cutaneous LE (CLE) lesions, along with elevated levels of IFN-alpha mRNA. The hypothesis in the current study was that local production of type I IFNs in CLE induces Th1-biased inflammation via induction of IFN-inducible chemokines such as IP10/CXCL10 leading to the recruitment of chemokine receptor CXCR3 expressing T-cells into skin lesions. Skin biopsies from 21 patients suffering from different types of active cutaneous LE were analysed for the expression of MxA, a protein specifically induced by type I interferons, the IFN-inducible protein IP10/CXCL10, and the chemokine receptor CXCR3, characteristic for Th1 cells, by immunohistochemistry. Additionally, peripheral CD4+ and CD8+ T-cells were investigated for the expression of MxA and CXCR3 by flow cytometry. Cutaneous LE lesions were characterized by strong expression of MxA indicating the induction of localized type I IFN signalling in the skin. Large numbers of infiltrating CXCR3 positive lymphocytes were detected in CLE skin lesions, and correlated closely with lesional MxA expression (epidermis: Spearman's rho = 0.56, p < 0.001; dermis: rho = 0.82, p < 0.001). Intracellular MxA levels of circulating CD4+ and CD8+ T-cells were significantly enhanced in patients with active CLE lesions. The percentage of peripheral T-cells expressing CXCR3 was significantly decreased in specific CLE subtypes. Expression of IP10/CXCL10 in the epidermis links type I IFN signalling and recruitment of CXCR3+ T cells. These results suggest an important role for type I interferon signalling in the pathogenesis of cutaneous lupus erythematosus. It is proposed that type I IFNs induce a Th1-biased inflammatory immune response, with recruitment of CXCR3-expressing T-lymphocytes into the skin.
IFN-I Score and Rare Genetic Variants in Children with Systemic Lupus Erythematosus.
Raupov R, Suspitsin E, Kalashnikova E, Sorokina L, Burtseva T, Argunova V Biomedicines. 2024; 12(6).
PMID: 38927451 PMC: 11200921. DOI: 10.3390/biomedicines12061244.
Shakiba S, Haddadi N, Afshari K, Lubov J, Raef H, Li R bioRxiv. 2024; .
PMID: 38260617 PMC: 10802382. DOI: 10.1101/2024.01.05.574422.
Lovato B, Fogagnolo L, Souza E, Silva L, Velho P, Cintra M An Bras Dermatol. 2023; 99(1):66-71.
PMID: 37783618 PMC: 10964360. DOI: 10.1016/j.abd.2023.02.007.
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D, de Vos L, Fetter T, Bragelmann C, Wenzel J Am J Clin Dermatol. 2023; 24(4):521-540.
PMID: 37140884 PMC: 10157137. DOI: 10.1007/s40257-023-00774-8.
Current Knowledge of the Molecular Pathogenesis of Cutaneous Lupus Erythematosus.
Miyagawa F J Clin Med. 2023; 12(3).
PMID: 36769633 PMC: 9918007. DOI: 10.3390/jcm12030987.